UiPath
PATH
$13.25
-2.50%
UiPath, Inc. is an enterprise software company that provides an end-to-end automation platform built on robotic process automation (RPA), computer vision, API integration, and artificial intelligence, used by organizations to automate repetitive workflows such as claims processing, employee onboarding, invoice-to-cash, loan applications, and customer service across the Americas, EMEA, and Asia-Pacific. The company is a recognized leader in the RPA and intelligent automation category, with a platform-centric model that layers AI capabilities on top of its original UI-automation foundation, though it faces intensifying competition from hyperscalers and broader workflow-automation suites. The current investor narrative centers on whether UiPath can transition from a high-growth, cash-burning RPA vendor into a sustainably profitable, AI-driven automation platform, a debate sharpened by the stock's roughly 24% single-day slide following its Q2 earnings report in early September 2026 despite what some commentators characterized as strong underlying results. Bulls point to the emerging "agentic AI" orchestration opportunity and UiPath's entrenched enterprise footprint as a re-rating catalyst, while bears question decelerating growth, heavy stock-based compensation, and the durability of its competitive moat against larger platform players.…
PATH
UiPath
$13.25
Related headlines
Investment Opinion: Should I buy PATH Today?
Rating: Hold. UiPath presents a balanced risk/reward profile: the stock trades at a modest forward P/E of 14.5x and 4.2x sales, with 17.3% revenue growth and $375M in trailing free cash flow, but the recent 24% post-earnings plunge and a 'Hold' consensus (mean 2.81) suggest that near-term uncertainty outweighs the compelling valuation. The average analyst target of $16.85 offers 25.8% upside, but the wide range ($10.98–$23.00) reflects divergent views on execution. Supporting evidence includes: 1) Revenue growth reaccelerated to 17.3% YoY in Q1 FY2027, up from 14.0% a year earlier; 2) Gross margin remains robust at 83%, though operating margin is only 3.8%; 3) The company generates substantial free cash flow ($375M TTM) and has a net cash position; 4) The forward P/E of 14.5x is below the broader software sector, and the PEG ratio is distorted by a one-time tax benefit. However, risks include: 1) Competitive threats from Microsoft and ServiceNow could pressure growth; 2) Operating margins are thin and vulnerable to any revenue shortfall; 3) The stock's high volatility (max drawdown -51.4%) and recent relative underperformance (-27.4% YTD vs. SPY) indicate market skepticism. The rating would upgrade to Buy if the stock sustains a close above $16 and forward guidance is raised, or downgrade to Sell if revenue growth falls below 12% or operating margins turn negative. Relative to its history and peers, PATH appears undervalued on a cash flow basis but fairly valued given growth and competitive risks.
Sign up to view all
PATH 12-Month Price Forecast
UiPath is a show-me story: the valuation is undemanding, and the balance sheet is strong, but the market is clearly concerned about growth durability and competitive positioning. The recent 24% post-earnings drop, despite decent results, signals that investors demand more evidence of a sustainable AI-driven growth trajectory. The base case (55% probability) sees the stock trading in the $15-18 range over the next 12 months, assuming mid-teens revenue growth and gradual margin improvement. I would upgrade to bullish if the company demonstrates two consecutive quarters of accelerating revenue growth and operating margin expansion above 8%. Conversely, a downgrade to bearish would occur if revenue growth falls below 12% or if a major customer loss is announced. The risk/reward is balanced, favoring a neutral stance until clearer catalysts emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UiPath's 12-month outlook, with a consensus price target around $16.85 and implied upside of +27.2% versus the current price.
Average Target
$16.85
0 analysts
Implied Upside
+27.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$11 - $23
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: PATH Investment Factors
The bull case rests on UiPath's reaccelerating revenue growth (17.3% YoY), robust free cash flow ($375M TTM), and a cheap forward P/E of 14.5x that seems to ignore its AI optionality. The bear case emphasizes the violent post-earnings sell-off (down 24% in a day), thin operating margins (3.8%), and intensifying competition from larger platform vendors. Currently, the bear evidence appears stronger because the market's negative reaction to Q2 results suggests deep concerns about the sustainability of growth and the company's ability to fend off hyperscalers. The single most important tension is whether UiPath can translate its agentic AI narrative into accelerating revenue and margin expansion—if it fails, the stock could retest its 52-week low of $9.20; if it succeeds, the upside to the $23 high target is substantial.
Bullish
- Revenue Growth Reaccelerated to 17.3% YoY: Q1 FY2027 revenue of $418.4M grew 17.3% year-over-year, up from 14.0% growth in the prior-year quarter. This acceleration, combined with a raised outlook in June 2026, suggests UiPath's AI-augmented automation platform is gaining traction despite competitive pressures.
- Strong Profitability and Cash Generation: The company reported net income of $22.5M (5.4% net margin) in Q1 FY2027 and generated $375.2M in trailing free cash flow. With a current ratio of 2.48 and debt-to-equity of just 0.039, the balance sheet is fortress-like, providing ample flexibility for buybacks or strategic investments.
- Attractive Valuation vs. Growth Prospects: PATH trades at a forward P/E of 14.5x and a PS ratio of 4.2x, well below the software sector median. The PEG ratio is distorted by a one-time tax benefit, but the forward earnings multiple implies the market is pricing in minimal growth despite 17% top-line expansion and a large net cash position.
- Agentic AI Opportunity Underappreciated: UiPath is positioned as a leader in the emerging agentic AI orchestration market, with its platform already automating complex workflows for thousands of enterprises. Recent articles highlight PATH as a top pick for this trend, and the company's RPA foundation provides a moat that pure-play AI startups lack.
Bearish
- Post-Earnings 24% Drop Signals Deep Skepticism: Despite reporting what some called strong Q2 results, PATH plummeted 24% on September 4, 2026, from $18.22 to $15.19. This violent reaction indicates that investors are highly sensitive to any perceived weakness in growth or guidance, and the stock has continued to drift lower to $13.39.
- Operating Margins Remain Razor-Thin: Operating margin is just 3.8% on a trailing basis, and Q1 FY2027 operating income was only $30.4M (7.3% margin). While gross margin is high at 83%, heavy spending on R&D ($92.9M) and SG&A ($220.6M) consumes nearly all gross profit, leaving little room for error.
- Competitive Threats from Hyperscalers: Microsoft, ServiceNow, and other large platform players are aggressively integrating automation and AI capabilities into their suites. UiPath's moat may erode as customers prefer bundled solutions, potentially pressuring pricing and win rates.
- Valuation Not as Cheap as It Appears: The trailing P/E of 24.2x is inflated by a one-time tax benefit in Q3 FY2026 that boosted net income. On an EV/EBITDA basis, PATH trades at 50.9x, which is expensive for a company with mid-teens growth. The forward P/E of 14.5x relies on EPS estimates that may prove optimistic.
PATH Technical Analysis
Beta
1.02
1.02x market volatility
Max Drawdown
-51.4%
Largest decline past year
52-Week Range
$9-$20
Price range past year
Annual Return
+0.8%
Cumulative gain past year
| Period | PATH Return | S&P 500 |
|---|---|---|
| 1m | -19.2% | +1.0% |
| 3m | +28.5% | +5.5% |
| 6m | +20.0% | +19.9% |
| 1y | +0.8% | +16.0% |
| ytd | -16.6% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PATH Fundamental Analysis
Quarterly Revenue
$418382000.0B
2026-04
Revenue YoY Growth
+17.3%
YoY Comparison
Gross Margin
81.1%
Latest Quarter
Free Cash Flow
$375234000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PATH Overvalued?
PE
24.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~96x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
50.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but noteworthy. UiPath's debt-to-equity ratio is a negligible 0.039, and it holds a current ratio of 2.48, indicating a strong balance sheet with ample liquidity. However, operating margins are thin at 3.8%, and the company relies on high gross margins (83%) to cover hefty R&D and SG&A expenses. Any slowdown in revenue growth could quickly turn operating income negative, as seen in prior quarters. Additionally, stock-based compensation remains a significant non-cash expense that dilutes shareholders and obscures true profitability. Revenue concentration in the Americas and dependence on large enterprise deals add cyclicality, while the recent 24% post-earnings drop highlights how sensitive the stock is to guidance. Market and competitive risks are elevated. The stock's beta of 1.02 suggests it moves roughly in line with the market, but its recent relative strength has been poor: -14.2% vs. SPY over the past month and -27.4% YTD. Valuation compression is a real threat if growth decelerates; the forward P/E of 14.5x may seem low, but it is based on EPS estimates that could be revised down. Competition from Microsoft, ServiceNow, and other automation platforms is intensifying, and UiPath's RPA-centric heritage may become a liability as AI-native solutions emerge. Regulatory risks are minimal, but macro sensitivity could hurt enterprise IT spending. The worst-case scenario involves a continued slowdown in new customer additions, competitive pricing pressure, and a miss on forward guidance, leading to a sharp de-rating. In that scenario, the stock could fall to its 52-week low of $9.20, representing a 31% decline from the current $13.39. If the bear case fully materializes, the analyst low target of $10.98 implies a 18% downside, but a more severe outcome could see the stock revisit its all-time low near $9, a 33% drop. The maximum drawdown over the past year was -51.37%, underscoring the potential for significant capital loss if the investment thesis deteriorates.
FAQ
The key risks include: 1) Competitive risk: Microsoft and ServiceNow are integrating automation and AI into their suites, potentially eroding UiPath's market share and pricing power. 2) Financial risk: Operating margins are thin at 3.8%, and any revenue shortfall could lead to losses; stock-based compensation dilutes shareholders. 3) Market risk: The stock is volatile (beta 1.02) and has underperformed the S&P 500 by 27.4% YTD, with a max drawdown of 51.4% in the past year. 4) Execution risk: The company must successfully transition from RPA to agentic AI, a complex technological shift. The most severe risk is a growth slowdown that triggers a de-rating to the 52-week low of $9.20, representing a 31% decline from current levels.
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $20-23, driven by successful AI monetization and margin expansion. Base case (55% probability) targets $15-18, assuming steady mid-teens growth and gradual margin improvement. Bear case (20% probability) targets $9.20-11.00, reflecting competitive losses and a growth slowdown. The base case is most likely, hinging on the assumption that UiPath maintains revenue growth above 15% and improves operating margins to 5-7%. Analyst average target of $16.85 aligns with our base case. Key catalysts include Q3 earnings, agentic AI product announcements, and competitive dynamics.
PATH appears undervalued on a forward earnings basis but fairly valued on a trailing cash flow basis. The forward P/E of 14.5x is well below the software sector median, and the PS ratio of 4.2x is modest for a company growing revenue at 17%. However, the trailing EV/EBITDA of 50.9x is high, reflecting currently depressed profitability. The market seems to be pricing in mid-teens growth and gradual margin improvement, but not a dramatic acceleration. Compared to its own history, the stock is trading near the lower end of its valuation range since IPO. If UiPath can expand operating margins to 10%+, the stock could re-rate higher; if growth stalls, the current multiple may prove optimistic.
PATH is a reasonable buy for investors with a long-term horizon and tolerance for volatility, but it is not a screaming bargain. The stock trades at a forward P/E of 14.5x and 4.2x sales, with 17.3% revenue growth and $375M in trailing free cash flow. Analyst consensus is 'Hold' with an average target of $16.85, implying 25.8% upside, but the recent 24% post-earnings drop shows the market is skeptical. The biggest downside risk is competitive pressure from Microsoft and ServiceNow, which could slow growth and compress margins. For risk-averse investors, waiting for clearer signs of sustainable profitability is prudent; for those with a higher risk appetite, the current valuation offers an attractive entry point if the AI narrative plays out.
PATH is better suited for long-term investors with a 2-3 year horizon who can tolerate volatility. The company is in a transition phase, investing heavily in AI while defending its RPA core, and near-term earnings may be choppy. The stock does not pay a dividend and has a beta of 1.02, so it offers no income and moves with the market. Short-term trading is risky due to the stock's history of sharp post-earnings moves (e.g., -24% in a day). A minimum holding period of 18-24 months is advisable to allow the AI strategy to mature and potentially drive multiple expansion. Investors should monitor quarterly results closely and reassess if growth falls below 12% or if competitive threats intensify.
